Acute paralysis following "a bad potato": A case of botulism

Canadian Journal of Anesthesia

Volumn 52, Issue 4, 2005, Pages 433-436

  Bhutani, Mohit ^a   Ralph, Edward ^a   Sharpe, Michael D ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN A;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; BIOCHEMISTRY; BLOOD CELL COUNT; BLOOD SAMPLING; BOTULISM; CASE REPORT; CLOSTRIDIUM BOTULINUM; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE; DETERIORATION; DIAGNOSTIC PROCEDURE; ENDOTRACHEAL INTUBATION; FECES ANALYSIS; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; INGESTION; LUMBAR PUNCTURE; MALE; MUSCLE STRENGTH; NERVE FUNCTION; NEUROMUSCULAR FUNCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALYSIS; PHYSICAL EXAMINATION; POTATO; PRIORITY JOURNAL; SENSATION; STOMACH CONTENT; TREATMENT PLANNING; VISUAL IMPAIRMENT;

EID: 19944384596     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03016290     Document Type: Article

References (14)

1. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States. A clinical and epidemiologic review. Ann Intern Med 1998; 129: 221-8.
2. Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol 1995; 195: 55-75.
3. Public Health Agency of Canada. Canadian Communicable Disease Report. URL available at: www.phac-aspc.gc.ca. 1996; 22: 21.
4. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon. Medical and public health management. JAMA 2001; 285: 1059-70.
5. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.
6. Hatheway CL. Botulism. In: Balows A, Hausler WH, Lennette EH (Eds). Laboratory Diagnosis of Infectious Diseases: Principles and Practice, Vol 1. New York: Springer-Verlag; 1988: 111.
7. Szabo EA, Pemberton JM, Gibson AM, Eyles MJ, Desmarchelier PM. Polymerase chain reaction for detection of Clostridium botulinum. types A, B and E in food, soil and infant faeces. J Appl Bacteriol 1994; 76: 539-45.
8. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998; 21: 701-10.
9. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B and E. J Infect Dis 1984; 150: 407-12.
10. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76: 794-8.
11. Chang GY, Ganguly G. Early antitoxin treatment in wound botulism results in better outcome. Eur Neurol 2003; 49: 151-3.
12. Sandrock CE, Murin S. Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest 2001; 120: 562-6.
13. Hibbs RG, Weber JT, Corwin A, et al. Experience with the use of an investigational F(ab') heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 1996; 23: 337-40.
14. Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981; 68: 50-4.